Request Demo
Recent blog posts
Latest Hotspot
8 min read
Glucose transporter type 1 deficiency syndrome Indication Strategy Report 2026: SLC2A1, Trials and Deals
30 July 2026
2026 Glucose transporter type 1 deficiency syndrome indication strategy covering epidemiology, SLC2A1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Cerebral folate deficiency Indication Strategy Report 2026: FOLR1, Trials and Deals
30 July 2026
2026 Cerebral folate deficiency indication strategy covering epidemiology, FOLR1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Sepiapterin reductase deficiency Indication Strategy Report 2026: SPR, Trials and Deals
30 July 2026
2026 Sepiapterin reductase deficiency indication strategy covering epidemiology, SPR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Dopamine transporter deficiency syndrome Indication Strategy Report 2026: SLC6A3, Trials and Deals
30 July 2026
2026 Dopamine transporter deficiency syndrome indication strategy covering epidemiology, SLC6A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Segawa syndrome Indication Strategy Report 2026: GCH1, Trials and Deals
30 July 2026
2026 Segawa syndrome indication strategy covering epidemiology, GCH1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Developmental and epileptic encephalopathy 2 Indication Strategy Report 2026: CDKL5, Trials and Deals
30 July 2026
2026 Developmental and epileptic encephalopathy 2 indication strategy covering epidemiology, CDKL5 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Rapid-onset dystonia-parkinsonism Indication Strategy Report 2026: ATP1A3, Trials and Deals
30 July 2026
2026 Rapid-onset dystonia-parkinsonism indication strategy covering epidemiology, ATP1A3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Developmental and epileptic encephalopathy 1 Indication Strategy Report 2026: STXBP1, Trials and Deals
30 July 2026
2026 Developmental and epileptic encephalopathy 1 indication strategy covering epidemiology, STXBP1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Pontocerebellar hypoplasia type 6 Indication Strategy Report 2026: RARS2, Trials and Deals
30 July 2026
2026 Pontocerebellar hypoplasia type 6 indication strategy covering epidemiology, RARS2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Brown-Vialetto-Van Laere syndrome Indication Strategy Report 2026: SLC52A2, Trials and Deals
30 July 2026
2026 Brown-Vialetto-Van Laere syndrome indication strategy covering epidemiology, SLC52A2 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Spinal muscular atrophy with respiratory distress type 1 Indication Strategy Report 2026: IGHMBP2, Trials and Deals
30 July 2026
2026 Spinal muscular atrophy with respiratory distress type 1 indication strategy covering epidemiology, IGHMBP2 biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 51 Indication Strategy Report 2026: AP4E1, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 51 indication strategy covering epidemiology, AP4E1 biology, active trials, transactions, unmet need, competition and…